Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

Basit Öğe Kaydı
dc.contributor.authorter Borg, Martijn J.
dc.contributor.authorvan Zonneveld, Monika
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorSenturk, Hakan
dc.contributor.authorAkarca, Ulus S.
dc.contributor.authorSimon, Christopher
dc.contributor.authorHansen, Bettina E.
dc.contributor.authorHaagmans, Bart L.
dc.contributor.authorde Man, Robert A.
dc.contributor.authorSchalm, Solko W.
dc.contributor.authorJanssen, Harry L. A.
dc.date.accessioned2019-10-27T19:17:28Z
dc.date.available2019-10-27T19:17:28Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.description.abstractIn chronic hepatitis B, it is difficult to predict an early therapeutic response. We investigated the viral decline during therapy with pegylated interferon alpha-2b (PEG-IFN) with or without lamivudine in 266 HBeAg-positive chronic hepatitis B patients. In patients treated with PEG-IFN and lamivudine, a uniform biphasic viral decline pattern was found during therapy and there were no marked differences in viral load between those who lost HBeAg at the end of follow-up (response) or not. In contrast, those treated with PEG-IFN monotherapy exhibited different viral decline patterns. A delayed decline of at least two log from baseline HBV DNA after week 4 but before week 32 was associated with the highest response rate (63%). In comparison, response was 52% for patients with an early decline (week 0-4), 38% for a late decline (week 32-52), 27% for a posttreatment decline (week 52-78) and 11% for patients with no substantial decline. The HBsAg loss was 22% in the delayed decline pattern compared to 4% for those with early decline and none for other decline patterns. In conclusion, different patterns of decline in viral load during treatment with PEG-IFN monotherapy were associated with different rates of HBeAg and HBsAg loss at the end of follow-up. Since there was a considerable response, even in patients with a late or posttreatment decline pattern, prediction of response based on viral decline during the first months of therapy was difficult.en_US
dc.identifier.doi10.1002/hep.21302en_US
dc.identifier.endpage727en_US
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.issue3en_US
dc.identifier.pmid16941701en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage721en_US
dc.identifier.urihttps://doi.org/10.1002/hep.21302
dc.identifier.urihttps://hdl.handle.net/11454/38391
dc.identifier.volume44en_US
dc.identifier.wosWOS:000240241900023en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofHepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titlePatterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment responseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu